The effectiveness of journals in exploration geophysics

Geophysics ◽  
1991 ◽  
Vol 56 (6) ◽  
pp. 844-858 ◽  
Author(s):  
Brian R. Spies
Keyword(s):  
Cost Effectiveness ◽  
Citation Analysis ◽  
Nearest Neighbor ◽  
Unit Cost ◽  
Cost Effective ◽  
Geophysical Research ◽  
For Profit ◽  
Not For Profit ◽  
One Year ◽  
Number Of Citations

A detailed citation analysis was conducted for fourteen major journals dealing with exploration geophysics, to judge their cost‐effectiveness and impact. The analysis was for papers published in 1984, so that papers had approximately five years of visibility at the time the citation analysis was conducted. In addition, a study was performed for Geophysics for the years 1980 to 1988, to assess the influence of the length of time a paper was in the literature. The leading journal, in terms of number of citations, was the Journal of Geophysical Research, which received an average of 17.4 citations per paper, followed by the Geophysical Journal of the Royal Astronomical Society (8.6) and Geophysics (5.4). Several journals average less than 1 citation per paper. For Geophysics, the average paper receives an extra 1.2 citations per year over the nine years studied. The percentage of nil citations decreases from 35 percent after one year, to 8 percent after 9 years. Four percent of papers receive 20 percent of all citations; these are the classic papers of exploration geophysics. Short notes, on average, receive half the number of citations as full papers. Self‐citations, which account for approximately one in five citations, do not appear to significantly affect the importance or relevance of a paper. When examined in terms of cost‐effectiveness, SEG publications rate very well. Geophysics and SEG Expanded Abstracts have the lowest cost per 1000 characters of all the journals studied. In terms of the number of citations per unit cost, Geophysics is more than twice as cost‐effective than its nearest neighbor, the Journal of Geophysical Research. The results also confirm those of earlier studies, that commercial journals are not as cost‐effective as those published by not‐for‐profit professional societies.

scholarly journals A one-year cost–utility analysis of REBOA versus RTACC for non-compressible torso haemorrhage

Trauma ◽  
2017 ◽  
Vol 21 (1) ◽  
pp. 45-54 ◽  
Author(s):  
Maxwell S Renna ◽  
Cristiano van Zeller ◽  
Farah Abu-Hijleh ◽  
Cherlyn Tong ◽  
Jasmine Gambini ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Effective ◽  
Quality Adjusted Life Year ◽  
Cost Utility ◽  
Incremental Cost Effectiveness Ratio ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Cost Effectiveness Ratio ◽  
One Year ◽  
Quality Adjusted Life

Introduction Major trauma is a leading cause of death and disability in young adults, especially from massive non-compressible torso haemorrhage. The standard technique to control distal haemorrhage and maximise central perfusion is resuscitative thoracotomy with aortic cross-clamping (RTACC). More recently, the minimally invasive technique of resuscitative endovascular balloon occlusion of the aorta (REBOA) has been developed to similarly limit distal haemorrhage without the morbidity of thoracotomy; cost–utility studies on this intervention, however, are still lacking. The aim of this study was to perform a one-year cost–utility analysis of REBOA as an intervention for patients with major traumatic non-compressible abdominal haemorrhage, compared to RTACC within the U.K.’s National Health Service. Methods A retrospective analysis of the outcomes following REBOA and RTACC was conducted based on the published literature of survival and complication rates after intervention. Utility was obtained from studies that used the EQ-5D index and from self-conducted surveys. Costs were calculated using 2016/2017 National Health Service tariff data and supplemented from further literature. A cost–utility analysis was then conducted. Results A total of 12 studies for REBOA and 20 studies for RTACC were included. The mean injury severity scores for RTACC and REBOA were 34 and 39, and mean probability of death was 9.7 and 54%, respectively. The incremental cost-effectiveness ratio of REBOA when compared to RTACC was £44,617.44 per quality-adjusted life year. The incremental cost-effectiveness ratio, by exceeding the National Institute for Health and Clinical Effectiveness’s willingness-to-pay threshold of £30,000/quality-adjusted life year, suggests that this intervention is not cost-effective in comparison to RTACC. However, REBOA yielded a 157% improvement in utility with a comparatively small cost increase of 31.5%. Conclusion Although REBOA has not been found to be cost-effective when compared to RTACC, ultimately, clinical experience and expertise should be the main factor in driving the decision over which intervention to prioritise in the emergency context.

scholarly journals One year later: A case study examining a community hospital’s administrative response to a debris flow

2019 ◽  
Vol 8 (2) ◽  
pp. 39
Author(s):  
Ann Gianola ◽  
Steven A. Fellows
Keyword(s):  
Los Angeles ◽  
Debris Flow ◽  
First Responders ◽  
Travel Agency ◽  
Trauma Patients ◽  
Santa Barbara ◽  
Seeking Safety ◽  
For Profit ◽  
Not For Profit ◽  
One Year

Santa Barbara, California was first impacted by the Thomas Fire in December 2017 only to be devastated by the Montecito Debris Flow less than two weeks later. Cottage Health, a not-for-profit health system that provides advanced tertiary and quaternary medical care for patients throughout the Central Coast of California, was at the forefront of first responders to those directly impacted by the debris flow. Santa Barbara Cottage Hospital (“SBCH”) (located 6 miles from the flow) treated 18 trauma patients, two first-responders, and 1 additional emergency patient later in the day, while Goleta Valley Cottage Hospital (“GVCH”) (located 12 miles from the flow) treated seven patients. Flooding and debris from the storm forced the closure of Highway 101 in both directions north and south for thirteen days. Highway 101 is the only major thoroughfare from Santa Barbara to Los Angeles and forced Cottage Health to implement an internal “travel agency,” in order to support Cottage Health clinicians to get to and from the two hospitals. The internal “travel agency” arranged transportation via planes, boats, vans and trains. In addition, the agency arranged accommodations utilizing local hotels, and an empty patient care unit in GVCH. Employees and board members opened up their homes to respond to more than 4,000 transportation and 900 overnight accommodation requests. Immediately following the disaster, licensed Cottage Health clinicians implemented a How We Heal: Trauma and Anxiety Support Group series to serve all Santa Barbara residents. The series is composed of How We Heal: Process Group, How We Heal: Skill Building/Seeking Safety Group and How We Heal: Survivor Group and one year later, continues to serve the community.

scholarly journals Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective

2020 ◽  
Vol 17 (12) ◽  
pp. 4339
Author(s):  
Savvas S. Ioannou ◽  
Yiola Marcou ◽  
Eleni Kakouri ◽  
Michael A. Talias
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Early Breast Cancer ◽  
Real World ◽  
Cost Effective ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Lifetime Horizon ◽  
Effectiveness Analysis ◽  
One Year

Introduction: This study is one of the first real-world cost-effectiveness analyses of one-year adjuvant trastuzumab used in HER2-positive early female breast cancer in comparison to chemotherapy alone. It is just the second one in Europe, the first one in Cyprus, and the fourth one worldwide ever carried out using real-world data. Methods: Using a Markov model (four health states), a cost-effectiveness analysis was carried out both over 20 years and for a lifetime horizon. The sampling method used in this study was the randomized sampling of 900 women. Results: The findings for the 20-year horizon showed that all trastuzumab arms were more cost-effective, with a willingness-to-pay threshold of only €60,000 per quality-adjusted life year (QALY) [incremental cost-effectiveness ratios (ICER): €40,436.10/QALY]. For the lifetime horizon, with thresholds of €20,000, €40,000, and €60,000/QALY, all trastuzumab arms were found to be more cost-effective (ICER: €17,753.85/QALY). Moreover, for the 20-year and the lifetime horizons, with thresholds of €20,000/QALY, €40,000/QALY, and €60,000/QALY, the most cost-effective of the three subgroups (anthracyclines and then trastuzumab, no anthracyclines and then trastuzumab, and anthracyclines, taxanes, and trastuzumab) was that of anthracyclines and then trastuzumab (ICER: €18,301.55/QALY and €8954.97/QALY, respectively). Conclusions: The study revealed that adjuvant trastuzumab for one year in female HER2-positive early breast cancer can be considered cost-effective.

Enterprise and care

2016 ◽  
Author(s):  
Catherine Needham ◽  
Kerry Allen ◽  
Kelly Hall
Keyword(s):  
Service Delivery ◽  
Quantitative Research ◽  
Public Services ◽  
Cost Effective ◽  
Social Enterprises ◽  
For Profit ◽  
Not For Profit ◽  
The Social ◽  
Delivery Models ◽  
Micro Enterprises

This chapter focuses on enterprise and care considering the contribution that new delivery models such as social enterprises make within public services more broadly and care in particular. The chapter also considers the ambiguity of the social enterprise label and its capacity to be claimed by a range of governance types, including the for-profit as well as the not-for-profit. The chapter then draws together the evidence on micro-enterprises into four research hypotheses that are tested in later chapters of the book, through qualitative and quantitative research. These are derived from the policy claims that are made by proponents of micro forms of service delivery: that micro-enterprises are more personalised, innovative, cost-effective and outcomes-oriented than larger organisations.

scholarly journals The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients

Anemia ◽  
2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Omar Maoujoud ◽  
Samir Ahid ◽  
Hocein Dkhissi ◽  
Zouhair Oualim ◽  
Yahia Cherrah
Keyword(s):  
Cost Effectiveness ◽  
Health Economic Evaluation ◽  
Cost Effective ◽  
Erythropoietin Receptor ◽  
Chronic Haemodialysis ◽  
Period 2 ◽  
Receptor Activator ◽  
Anaemia Management ◽  
One Year ◽  
The Cost

Introduction. The aim of this study was to compare the cost-effectiveness of continuous erythropoietin receptor activator (CERA) once monthly to epoetin beta (EpoB) thrice weekly to maintain haemoglobin (Hb) within the range 10.5–12 g/dL.Methods. Prospective cohort study and cost-effectiveness analysis. Chronic haemodialysis patients (CHP), being treated with EpoB, were selected for two periods of follow-up: period 1, maintaining prior treatment with EpoB, and period 2, conversion to CERA once monthly. Hb concentrations and costs were measured monthly. Health care payer perspective for one year was adopted.Results. 75 CHP completed the study, with a mean age of52.9±14.3years. Baseline Hb was11.14±1.18 g/dL in EpoB phase and11.46±0.79 g/dL in CERA phase; we observed a significant increase in the proportion of patients successfully treated (Hb within the recommended range), 65.3% versus 70.7%,p: 0.008, and in the average effectiveness by 4% (0.55 versus 0.59). Average cost-effectiveness ratios were 6013.86 and 5173.64$, with an ICER CERA to EpoB at −6457.5$.Conclusion. Our health economic evaluation of ESA use in haemodialysis patients suggests that the use of CERA is cost-effective compared with EpoB.

scholarly journals Economic Evaluation of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to Universal use of Ticagrelor or Clopidogrel in Qatar

2020 ◽  
Author(s):  
Sawsan Ibrahim AlMukdad ◽  
Hazem Elewa ◽  
Daoud Al-Badriyeh
Keyword(s):  
Cost Effectiveness ◽  
Incremental Cost ◽  
Antiplatelet Therapy ◽  
Cost Effective ◽  
Cyp2c19 Genotype ◽  
Life Years ◽  
One Year ◽  
The One ◽  
Guided Therapy

Background: Patients having CYP2C19 loss-of-function alleles and receiving clopidogrel are at higher risk of adverse cardiovascular outcomes. Ticagrelor is a more effective and expensive antiplatelet that is unaffected by the CYP2C19 polymorphism. The main aim of the current research is to evaluate the cost-effectiveness among CYP2C19 genotype-guided therapy, universal ticagrelor, and universal clopidogrel after a percutaneous coronary intervention (PCI). Methods: A two-part simulation model, including a one-year decision-analytic model and a 20-year followup Markov model, was created to follow the use of (i) universal clopidogrel, (ii) universal ticagrelor, and (iii) genotype-guided antiplatelet therapy. Outcome measures were the incremental cost-effectiveness ratio (ICER, cost/success) and incremental cost-utility ratio (ICUR, cost/qualityadjusted life years [QALY]). Therapy success was defined as survival without myocardial infarction, stroke, cardiovascular death, stent thrombosis, and no therapy discontinuation because of adverse events, i.e. major bleeding and dyspnea. The model was based on a multivariate analysis, and a sensitivity analysis confirmed the robustness of the model outcomes. Results: Against universal clopidogrel, genotype-guided therapy was cost-effective over the one-year duration (ICER, USD 6,102 /success), and dominant over the long-term. Genotype-guided therapy was dominant over universal ticagrelor over the one-year duration and cost-effective over the long term (ICUR, USD 1,383 /QALY). Universal clopidogrel was dominant over ticagrelor over the short term, and cost-effective over the long-term (ICUR, 10,616 /QALY). Conclusion: CYP2C19 genotype-guided therapy appears to be the preferred antiplatelet strategy, followed by universal clopidogrel, and then universal ticagrelor for post-PCI patients in Qatar.

scholarly journals Cost Effectiveness of Therapist Delivered Cognitive Behavioural Therapy and Web-Based Self-Management in Irritable Bowel Syndrome: The ACTIB Randomised Trial

2021 ◽  
Author(s):  
Paul McCrone ◽  
Hazel Everitt ◽  
Sabine Landau ◽  
Paul Little ◽  
Felicity L. Bishop ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Service Use ◽  
Randomised Trial ◽  
Cost Effective ◽  
Behavioural Therapy ◽  
Treatment As Usual ◽  
Web Based ◽  
Life Years ◽  
Irritable Bowel ◽  
One Year

Abstract Background Telephone therapist delivered CBT (TCBT) and web-based CBT (WCBT) have been shown to be significantly more clinically effective than treatment as usual (TAU) at reducing IBS symptom severity and impact at 12 months in adults with refractory IBS. In this paper we assess the cost-effectiveness of the interventions. Methods Participants were recruited from 74 general practices and three gastroenterology centres in England. Interventions costs were calculated, and other service use and lost employment measured and costed for one-year post randomisation. Quality-adjusted life years (QALYs) were combined with costs to determine cost-effectiveness of TCBT and WCBT compared to TAU.Results TCBT cost £956 more than TAU (95% CI, £601 to £1435) and generated 0.0429 more QALYs. WCBT cost £224 more than TAU (95% CI, -£11 to £448) and produced 0.029 more QALYs. Compared to TAU, TCBT had an incremental cost per QALY of £22,284 while the figure for WCBT was £7724. After multiple imputation these ratios increased to £27,436 and £17,388 respectively. Including lost employment and informal care, TCBT had costs that were on average £866 lower than TAU (95% CI, -£1133 to £2957), and WCBT had costs that were £1028 lower than TAU (95% CI, -£448 to £2580).Conclusions TCBT and WCBT resulted in more QALYs and higher costs than TAU. Complete case analysis suggests both therapies are cost-effective from a healthcare perspective. Imputation for missing data reduces cost-effectiveness but WCTB remained cost-effective. If the reduced societal costs are included both interventions are likely to be more cost-effective.Trial registration ISRCTN44427879 (registered 18.11.13)

scholarly journals Economic evaluation of Health Extension Program packages in Ethiopia

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0246207
Author(s):  
Lelisa Fekadu Assebe ◽  
Wondesen Nigatu Belete ◽  
Senait Alemayehu ◽  
Elias Asfaw ◽  
Kora Tushune Godana ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Prevention And Control ◽  
Unit Cost ◽  
Family Health ◽  
Cost Effective ◽  
Health Extension Program ◽  
Per Capita ◽  
The Cost ◽  
And Control ◽  
Extension Program

Background Ethiopia launched the Health Extension Program (HEP) in 2004, aimed at ensuring equitable community-level healthcare services through Health Extension Workers. Despite the program’s being a flagship initiative, there is limited evidence on whether investment in the program represents good value for money. This study assessed the cost and cost-effectiveness of HEP interventions to inform policy decisions for resource allocation and priority setting in Ethiopia. Methods Twenty-one health care interventions were selected under the hygiene and sanitation, family health services, and disease prevention and control sub-domains. The ingredient bottom-up and top-down costing method was employed. Cost and cost-effectiveness were assessed from the provider perspective. Health outcomes were measured using life years gained (LYG). Incremental cost per LYG in relation to the gross domestic product (GDP) per capita of Ethiopia (US$852.80) was used to ascertain the cost-effectiveness. All costs were collected in Ethiopian birr and converted to United States dollars (US$) using the average exchange rate for 2018 (US$1 = 27.67 birr). Both costs and health outcomes were discounted by 3%. Result The average unit cost of providing selected hygiene and sanitation, family health, and disease prevention and control services with the HEP was US$0.70, US$4.90, and US$7.40, respectively. The major cost driver was drugs and supplies, accounting for 53% and 68%, respectively, of the total cost. The average annual cost of delivering all the selected interventions was US$9,897. All interventions fall within 1 times GDP per capita per LYG, indicating that they are very cost-effective (ranges: US$22–$295 per LYG). Overall, the HEP is cost-effective by investing US$77.40 for every LYG. Conclusion The unit cost estimates of HEP interventions are crucial for priority-setting, resource mobilization, and program planning. This study found that the program is very cost-effective in delivering community health services.

scholarly journals Coverage outcomes (effects), costs, cost-effectiveness, and equity of two combinations of long-lasting insecticidal net (LLIN) distribution channels in Kenya: a two-arm study under operational conditions

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Eve Worrall ◽  
Vincent Were ◽  
Agnes Matope ◽  
Elvis Gama ◽  
Joseph Olewe ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Channel Model ◽  
Unit Cost ◽  
Continuous Distribution ◽  
Distribution Channel ◽  
Cost Effective ◽  
Distribution Channels ◽  
Distribution Data ◽  
Llin Distribution ◽  
Llin Ownership

Abstract Background Malaria-endemic countries distribute long-lasting insecticidal nets (LLINs) through combined channels with ambitious, universal coverage (UC) targets. Kenya has used eight channels with variable results. To inform national decision-makers, this two-arm study compares coverage (effects), costs, cost-effectiveness, and equity of two combinations of LLIN distribution channels in Kenya. Methods Two combinations of five delivery channels were compared as ‘intervention’ and ‘control’ arms. The intervention arm comprised four channels: community health volunteer (CHV), antenatal and child health clinics (ANCC), social marketing (SM) and commercial outlets (CO). The control arm consisted of the intervention arm channels except mass campaign (MC) replaced CHV. Primary analysis used random sample household survey data, service-provider costs, and voucher or LLIN distribution data to compare between-arm effects, costs, cost-effectiveness, and equity. Secondary analyses compared costs and equity by channel. Results The multiple distribution channels used in both arms of the study achieved high LLIN ownership and use. The intervention arm had significantly lower reported LLIN use the night before the survey (84·8% [95% CI 83·0–86·4%] versus 89·2% [95% CI 87·8–90·5%], p < 0·0001), higher unit costs ($10·56 versus $7·17), was less cost-effective ($86·44, 95% range $75·77–$102·77 versus $69·20, 95% range $63·66–$77·23) and more inequitable (Concentration index [C.Ind] = 0·076 [95% CI 0·057 to 0·095 versus C.Ind = 0.049 [95% CI 0·030 to 0·067]) than the control arm. Unit cost per LLIN distributed was lowest for MC ($3·10) followed by CHV ($10·81) with both channels being moderately inequitable in favour of least-poor households. Conclusion In line with best practices, the multiple distribution channel model achieved high LLIN ownership and use in this Kenyan study setting. The control-arm combination, which included MC, was the most cost-effective way to increase UC at household level. Mass campaigns, combined with continuous distribution channels, are an effective and cost-effective way to achieve UC in Kenya. The findings are relevant to other countries and donors seeking to optimise LLIN distribution. Trial registration The assignment of the intervention was not at the discretion of the investigators; therefore, this study did not require registration.

A Randomized Prospective Study of the Cost -Effectiveness of the Conventional Spike, O-Set, and Uvxd Techniques in Continuous Ambulatory Peritoneal Dialysis

1994 ◽  
Vol 14 (3) ◽  
pp. 255-260 ◽  
Author(s):  
Ignatius K.P. Cheng ◽  
Ching-Ying Chan ◽  
Suk-Wai Cheng ◽  
Joana F.M. Poon ◽  
Yu-Lian Ji ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Cost Effectiveness ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Cost Effective ◽  
Training Time ◽  
Outpatient Visits ◽  
Significant Difference ◽  
Hospital Stays ◽  
One Year ◽  
The Cost

Objective To compare the clinical outcome and cost-effectiveness of three techniques for continuous ambulatory peritoneal dialysis (CAPD): the conventional spike technique (C), the O-set (0), and UVXD (U, ultraviolet irradiation connection box). Design A randomized and prospective comparison of three CAPD techniques. Setting A tertiary referral and a satellite dialysis center.. Patients: One hundred patients with end-stage renal failure between 10 and 70 years of age, with good handeye coordination and not anticipated to receive a living related transplant within 6 months. Interventions Patients were randomized by referral to a table of random numbers to perform one of the three CAPD techniques. Main Outcome Measures Training time, details of peritonitis and exit-site infection (ESI) including the costs of antibiotic treatment, outpatient visits, hospital stays, technique, and patient survival were analyzed after a minimum follow-up period of one year. Results There were 38, 31, and 31 patients in groups C, 0, and U, respectively, and the total observation periods were 838,802, and 745 patient-months, respectively. The peritonitis rates for C, 0, and U were 21.5, 30.8, and 29.8 patient-months/episode, respectively. The corresponding ESI rates were 16.4,14.9, and 24 patient-months/ episode, respectively. When the time from the commencement of CAPD to the first infection was expressed using the Kaplan-Meier life table analysis, 39.5%, 67.7%, and 61.3% of patients in Groups C, 0, and U were free from peritonitis at one year (p = 0.088). The corresponding figures for ESI were 52.6%, 48.4%, and 61.3% (p = 0.35). There was no significant difference in technique survival in the three treatment groups. An analysis of the costs related to the use of antibiotics, outpatient visits, and hospital stays necessary for the treatment of peritonitis and ESI and those related to training time, additional equipment, and consumables required for the three CAPD techniques showed that, overall, the cost in 0 was the lowest, followed by U and C (U.S. $158, $170, and $179 per patient-month, respectively). Conclusion It was concluded that the O-set is a more cost-effective CAPD technique than UVXD, while both are more cost-effective than the conventional spike technique.

Sign in / Sign up

Export Citation Format

Share Document